e J o n g , 2 R i c h a r d Z u i d e r e n t 2 and J.M. F r a n s T r i j b e l s 2 ■Mercaptopurine, a hypoxanthine antimetabolite, is us the treatment o f acute lymphoblastic leukemia (ALL) 6-Mercaptopurine (6MP) is a hypoxanthine antimetabolite used in the treatment of acute lymphoblastic leukemia (ALL)/ It has metabolized before it exerts cytotoxic no intrinsic cytotoxic activity, but is converted into active ■mercapto-2,8-dihydroxypu methylmer roxypunne viously reported in plasma. This compound was found in high concentrations in plasma during high-dose 6-mercaptopurine infusions (1300 mg/m2 in 24 h). This previously unknown compound was identified by reversed-phase HPLC with absorbance detection and by gas chromatog raphy-mass spectrometry. The pathways leading to 6 -in e thy 1 m er cap t o -8 -hy d r o xy pu ii n e in vivo are not yet fully understood. In a group o f 17 patients treated widi four courses of high-dose 6-mercaptopurine infusions according to the ALL-8 treatment protocol o f the Dutch Childhood Leukemia Study Group, the steady-state concentrations of 6-methylmercapto-8-hydroxypurinc in plasma were oneof the parent drug concentrations, with wide interindividual variation. The formation o f high concentrations o f 6-methylmercapto-8-hydroxypurine in plasma, especially metabolites before it exerts its cytotoxic action. The first step in W e the anabolic padiway of 6MP is its conversion into the nucleotide, thioinosine monophosphate (Fig. 1 ). This compound is converted into thioguanosine monophosphate, which is cyto toxic after incorporation into DNA and RNA ///, or into methylthioinosine monophosphate, which is an inhibitor of the purine de novo synthesis [2j. 6MP can be methylated into 6-methyhnercaptopurine (6MeMP). 6MeMP ri (6MeMPR) is the product of the breakdown of methylthioitiosme monophosphate or of the méthylation of 6MP riboside. Xanthine oxidase (EG 1.2.3.2), which is mainly active in the liver and kidney [3] , catabolizes 6MP into thiouric acid (6-mercapto-2,8-dihydroxypurine). This oxidation occurs via 6-mercapto-Hhydroxypurine (6MBOHP) and to a lesser extent via thioxanthine (6-mercapto-2-hydroxypurine) [4] . Previous j humans demonstrated that 6MP and thiouric acid are the major compounds, and thioxanthine and 6MP riboside the minor ones, that are excreted in urine during 6MP administration ¡S-IOj, indicating that degradation of 6MP occurs mainly via xanthine oxidase. Another pathway leading to the inactivation of 6MP in in during the infusion, probably indicates another catabolic humans is desulfuradon of the drug, which probably occurs via pathway of high-dose 6-mercaptopurine, apart from its mcthylthiopurines [7J. conversion into thiouric acid.
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When treating patients with high-dose 6MP infusions, we found considerable amounts of a hitherto unknown compound INDEXING TERMS: acute lymphoblastic leukemia • methotrexate in plasma [11] . After purification, the compound was identified • drug metabolism • thiouric acid by HPLC and gas chromatography-mass spectrometry (GC-MS) as 6-methylmercapto-8-hydroxypurine (6MeM8QlIP). The presence of this metabolite of 6MP in plasma has not been described before and may point to another catabolic pathway of high-dose 6MP.
Patients and Methods

PATIENTS
Patients with ALL (n = 17) were treated in our center according to the treatment' protocol of the Dutch Childhood Leukemia Study Group (ALL 8 and JV, 0 -bis(tri 10 rnL/L trim ane (Pierce, Rockford, IL). We carried out the derivatization at 60 °C for 30 min, after which we diluted the mixture with 50 ¡iL of chloroform. The 6MeMBOHP calibrator was trimethylsilylated by the same procedure and used as a reference. To separate the products, we used a HP5890 gas chromatograph (HewlettPackard, Amsterdam, The Netherlands), using a 25 m X 0.32 mm (i.d.) CP-sil-8CB column with a film thickness of 0.12 ¡xm (Chrompack, Middelburg, 'The Netherlands) and split injection. The carrier gas was helium at a column head pressure of 48.3 kPa. The oven temperature was programmed from 70 °C to 280 °C.
The metabolite of 6MP was identified with a VG-trio-2 quadrupole mass spectrometer (Fisons Instruments, Cheshire, UK) in electron impact ionization mode at 70 eV and a source temperature of 200 °C. Scan measurements were performed from 40 to 650 amu with a scan time of 1 s and an intersean delay h) followed immediately by a high-dose 6MP infusion (1300 of 0.1 s. Selected ion recording measurements were performed r • m in 24 h, from 24 to 48 h •mg successive courses. When the paired f-tests did not reach significance (P <0.05), concentrations of 6MP and 6M eM 80H P reached during suc cessive courses were not significantly different. We also calcu lated the individual means of the lour courses for each patient; at we calculated each time point, from statistics for the four courses to 
Results
On the basis of their retention time and ultraviolet absorbance, we determined that none of th •eover, the ; :e spectra of the unknown compound e c in and of 6M eM 80H P were identical (Fig. 3) . The derivati zed form of the 6M eM 80H P :ator ; account for the unknown peak. In IIPLC, the a peak with a retention time of 22.8 min by GC, the mass com :rore in plasma e at 29 min, i.e., 1.5 min r. 1 we plasma, the peak 6MeM80ITP compound at 290 nm increased (Fig. 2A) . In a Fig. 2B) . 6MeM8QHP calibrator (Fig. 4, top 3.00 0,00 If î both of which displayed wide interindividual variation. For -window phase with one high-dose 6MP infusion and with the 6M eM 80HP, part of this variation may be caused by the wide xanthine oxidase inhibitor allopurinol [14, 15] contained a peak at 320 urn with the same retention time as 6M 8OHP, i.e., 1 mill ± 6 s before the peak of 6MP. This peak was present during and after the 6MP infusion, and the area under the peak was variation in thiopurine (TPMT; EC 2.1.1.67) activity. T P M T shows a genetic poly morphism, with 88.6% of the subjects demonstrating high activity and 11.1% intermediate activity. About 1 in 300 subjects 20-31% of that of 6MP in one patient (6MP steady-state 57 has undetectable T P M T activity [12[ . /¿mol/L) [14] and 6-11% in the other (6MP steady-state 35 placenta) [13] ow r is TPM T activity is highest in liver and kidney but has been /xrnol/L) [15] . W e received the 6M80I1P calibrator only redetected in all other tissues examined (erythrocytes, lymphocently from Dr. Elion. However, no more plasma from these s, thrombocytes, lymphoblasts, lung, intestine, brain, and two patients is available for analysis, so we cannot confirm that this peak was actually 6M 8OHP. The presence of this peak in formed in vivo is not known. Two the chromatograms of plasma of two patients with high 6MP metabolic routes may lead to the formation of this compound: steady-state concentrations and allopurinol treatment-and the inethylation of 6M 80H P or 8-oxidation of 6MeMP. Evidences absence of it in all chromatograms of the 17 patients treated with exist from in vitro studies that oxidation of 6MP by xanthine high-dose 6MP without allopurinol-suggest that 6M 80I1P oxidase preferentially occurs first at the 8 position and then at can be produced in vivo and is rapidly further oxidized by position 2, in contrast to hypoxanthine, which is first oxidized on C-2 and subsequently on C-8 [4[. 6MBOHP has not been described in vivo, which may be explained by a higher activity of xanthine oxidase towards 6M 8QHP than towards 6MP [4] . W e did not find 6 M 80H P in plasma or urine of the 17 patients. In humans, désulfuration of the thiopurine with formation of inorganic sulfate appears to occur via the methyla larger amount of sulfate than the Hinnes, thiopurines do [7] , Because désulfuration of In conclusion, the present study shows that 6MeM8QHP is a major metabolite of 6MP in plasma during high-dose 6MP infusions, whereas smaller amounts of 6MeMP, 6MeMPR, and thioxanthine are produced in plasma [19] . 
